Instructions Antares solution for injection 50 mg/ml ampoule 4 ml No. 10
Warehouse
active ingredient: morpholinium salt of thiazide acid;
1 ml of solution contains:
morpholinium salt of thiazide acid, calculated as 100% substance - 50 mg, which is equivalent to 33.3 mg of thiazide acid;
Excipient: water for injections.
Dosage form
Solution for injection.
Main physicochemical properties:
clear, colorless or slightly yellowish liquid.
Pharmacotherapeutic group
Cardiological drugs Other cardiological drugs. ATX code C01E B23.
Pharmacological properties
Pharmacodynamics.
The pharmacological effect of thiazide acid is due to its anti-ischemic, membrane-stabilizing, antioxidant, and immunomodulatory effects.
The effect of the drug is realized by enhancing the compensatory activation of anaerobic glycolysis and activation of oxidation processes in the Krebs cycle with the preservation of the intracellular fund of adenosine triphosphate. The presence in the structure of the thiazolidinedione molecule of sulfur thiol, which is characterized by redox properties, and tertiary nitrogen, which binds excess hydrogen ions, causes the activation of the antioxidant system. The strong reducing properties of the thiol group cause a reaction with reactive oxygen species and lipid radicals. Reactivation of antiradical enzymes - superoxide dismutase, catalase and glutathione peroxidase - prevents the initiation of reactive oxygen species.
Thiazide acid inhibits lipid oxidation processes in ischemic areas of the myocardium, reduces myocardial sensitivity to catecholamines, prevents progressive inhibition of cardiac contractile function, stabilizes and reduces the area of myocardial necrosis and ischemia, respectively. Improvement of the rheological properties of blood is achieved by activating the fibrinolytic system. Improvement of myocardial metabolic processes, increasing its contractility, and promoting normalization of heart rhythm allow us to recommend thiazide acid for the treatment of patients with various forms of ischemic heart disease.
Pharmacokinetics.
The maximum concentration of thiazide acid in plasma is reached after 0.84 hours after intramuscular administration, after 0.1 hours after intravenous administration. Binding to blood proteins does not exceed 10%. Thiazide acid accumulates mainly in the kidneys - 31%. In significant quantities, it accumulates in the colon, heart, spleen, and to a lesser extent - in the small intestine and lungs (1-2%).
Indication
In the complex treatment of ischemic heart disease: angina pectoris, myocardial infarction.
Contraindication
Hypersensitivity to thiazide acid;
Acute renal failure.
Pregnancy and breastfeeding.
Children's age (up to 18 years).
Interaction with other drugs and other types of interactions.
Antares can be used in combination with basic treatment for coronary heart disease.
Use during pregnancy or breastfeeding
Experience with the use of the drug during pregnancy or breastfeeding is insufficient.
Ability to influence reaction speed when driving vehicles or other mechanisms
In case of adverse reactions from the central and peripheral nervous system, caution should be exercised when driving vehicles and working with other complex mechanisms.
Method of administration and doses
In case of myocardial infarction and unstable angina, Antares should be administered intravenously slowly in 2 ml of a 50 mg/ml solution (100 mg) at a rate of 2 ml/min or intravenously dripped at a rate of 20–30 drops per minute (2 ml of a 50 mg/ml solution is diluted in 150–250 ml of 0.9% sodium chloride solution), or intramuscularly in 2 ml of a 50 mg/ml solution (100 mg) 2–3 times a day. The course of treatment is 14 days.
For angina pectoris, Antares is administered intramuscularly at 4 ml of 50 mg/ml solution 2 times a day (daily dose – 400 mg). The course of treatment is 14 days.
Children
Experience with the use of the drug in children is insufficient.
Overdose
In case of overdose, the concentration of sodium and potassium in the urine increases. In such cases, the drug should be discontinued. Treatment is symptomatic.
Adverse reactions
The drug is usually well tolerated. In patients with increased individual sensitivity, the following may occur:
Skin and subcutaneous tissue disorders: itching, skin hyperemia, rash, urticaria;
from the immune system: against the background of the use of other drugs, cases of angioedema, anaphylactic shock have been described;
others: fever, chills and changes at the injection site.
Patients, mainly elderly, may experience the following when taking other medications:
from the central and peripheral nervous system: general weakness, dizziness, tinnitus, headache;
Cardiovascular system: tachycardia, arterial hypertension; decrease in blood pressure;
Gastrointestinal: dyspeptic symptoms, including dry mouth, nausea, bloating, vomiting;
Respiratory system: shortness of breath and suffocation.
Expiration date
3 years.
Storage conditions
Store in the original packaging at a temperature not exceeding 25°C. Keep out of the reach of children.
Packaging
2 ml in an ampoule, 10 ampoules in a contour cell packaging, 1 contour cell packaging in a pack.
4 ml in an ampoule, 5 ampoules in a contour cell packaging, covered with film, 2 contour cell packaging, covered with film, in a pack.
Vacation category
According to the recipe.
Producer
PJSC "Halychpharm".
Location of the manufacturer and its business address
Ukraine, 79024, Lviv, Opryshkivska St., 6/8.
